Rxcurve
HCPCS J0738 · per 1 MG

Hiv prep, inj, lenacapavir

Products billed under this code include Yeztugo.

Payment limit per 1 MG, by effective quarter, 4Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J0738

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Yeztugo Gilead Sciences INC. 61958-3402-01 927 $14,846.832

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $16.016 −$0.065 1 MG Hiv prep, inj, lenacapavir v1, posted September 17, 2026
3Q26 $16.081 −$0.022 1 MG Hiv prep, inj, lenacapavir v1, posted September 15, 2026
2Q26 $16.103 −$0.03 1 MG Hiv prep, inj, lenacapavir v1, posted September 15, 2026
1Q26 $16.133 $0.00 1 MG Hiv prep, inj, lenacapavir v1, posted September 15, 2026
4Q25 $16.133 – 1 MG Hiv prep, inj, lenacapavir v1, posted September 8, 2026

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files